Last year IMU received Fast Track designation and ODD and then excellent clinical trial update for Azer-Cel. Some biotech start-up investor would consider them to be "some game changing events". We are waiting for further positive clinical trial updates from VAXINIA, OASIS and Azer-Cel and eventually a T/O from BP once they've seen enough data so there won't be any first revenue per-se from IMU........
IMU Price at posting:
3.9¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)